2001
DOI: 10.1091/mbc.12.8.2556
|View full text |Cite
|
Sign up to set email alerts
|

Proteasome Inhibitors Block a Late Step in Lysosomal Transport of Selected Membrane but not Soluble Proteins

Abstract: The ubiquitin-proteasome pathway acts as a regulator of the endocytosis of selected membrane proteins. Recent evidence suggests that it may also function in the intracellular trafficking of membrane proteins. In this study, several models were used to address the role of the ubiquitin-proteasome pathway in sorting of internalized proteins to the lysosome. We found that lysosomal degradation of ligands, which remain bound to their receptors within the endocytic pathway, is blocked in the presence of specific pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

5
74
0

Year Published

2002
2002
2019
2019

Publication Types

Select...
7
2
1

Relationship

2
8

Authors

Journals

citations
Cited by 110 publications
(79 citation statements)
references
References 54 publications
5
74
0
Order By: Relevance
“…Very recently, the involvement of both proteasome and lysosomes in the degradation pathway of wt AQP2 in a mouse renal collecting duct cell line was reported. 44 Thus, as observed for other membrane proteins, 45,46 the final degradative pathway for wt AQP2 and misrouted E258K AQP2 seems to involve both the proteasome and lysosomes. However, the T126M AQP2 and the E258K AQP2 expressed in clone 9 hepatocytes seem to be recognized by different quality control mechanisms and become efficiently degraded despite the fact that one is retained in the ER and the other is being misrouted to late endosomes and lysosomes.…”
Section: Discussionmentioning
confidence: 62%
“…Very recently, the involvement of both proteasome and lysosomes in the degradation pathway of wt AQP2 in a mouse renal collecting duct cell line was reported. 44 Thus, as observed for other membrane proteins, 45,46 the final degradative pathway for wt AQP2 and misrouted E258K AQP2 seems to involve both the proteasome and lysosomes. However, the T126M AQP2 and the E258K AQP2 expressed in clone 9 hepatocytes seem to be recognized by different quality control mechanisms and become efficiently degraded despite the fact that one is retained in the ER and the other is being misrouted to late endosomes and lysosomes.…”
Section: Discussionmentioning
confidence: 62%
“…Because the binding site of CHIP extends downstream of amino acid 334, it might mean that removing this binding site also would eliminate the necessity of CHIP. This is reminiscent of the involvement of the proteasome: its action is required for the endocytosis of the full-length receptor but is dispensable for a receptor truncated after amino acid amino acid 366 (55). However, the GHR truncated at 334 might still have sufficient binding affinity for CHIP to act as a necessary factor for endocytosis of the GHR334.…”
Section: Discussionmentioning
confidence: 99%
“…Bars, 20 m. Representative images from three independent experiments are shown. endocytic pathway (37,38,39,40). One suggested mechanism proposes that the inhibition of proteasome activity interferes with transport by perturbing the requisite protein mono-ubiquitination cycle due to decreased availability of free ubiquitin and increased steady state accumulation of mono-and multiubiquitinated proteins.…”
Section: Figmentioning
confidence: 99%